NCT05401786 2026-03-12
RAD-IO
The Netherlands Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
24 trialsNCT03565783 2026-02-25
Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05882734 2026-02-17
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
EMD Serono
Phase 1/2 Active not recruiting
NCT03233139 2026-02-12
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
Regeneron Pharmaceuticals
Phase 1 Active not recruiting
NCT04862650 2026-02-10
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT06190951 2026-02-10
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT02651662 2026-02-02
CLIO-1
Regeneron Pharmaceuticals
Phase 1 Active not recruiting
NCT03491683 2026-01-28
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
NCT05785767 2026-01-22
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
Phase 2/3 Active not recruiting
NCT05800015 2026-01-22
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals
Phase 2/3 Active not recruiting
NCT06161441 2026-01-12
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT05704634 2025-10-27
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03969004 2025-09-19
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT04387084 2025-09-05
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
NCT05574101 2025-08-08
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04305795 2025-06-19
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Rakuten Medical, Inc.
Phase 1/2 Active not recruiting
NCT04706715 2025-05-31
LAG3 PET Imaging in Advanced Solid Tumors
University Medical Center Groningen
Phase 1/2 Active not recruiting
NCT05608291 2025-05-13
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT03916627 2025-04-11
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT04050436 2025-01-27
CERPASS
Replimune Inc.
Phase 2 Active not recruiting
NCT05669989 2025-01-23
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Sanofi
Phase 2 Active not recruiting
NCT05878288 2024-11-21
DISCERN
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting
NCT03294083 2022-10-27
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
SillaJen, Inc.
Phase 1/2 Active not recruiting